May 25, 2022

30+ individuals and organisations call for urgent global action to reduce premature deaths from lung cancer – and offer collaborative recommendations to do so

 

At the World Health Organisation’s 75th World Health Assembly, the Lung Cancer Collaboration (LCC) convened at an important side event to launch their new report, ‘Urgent, coordinated global action on lung cancer’, which offers clear recommendations for governments to target action and investment in lung cancer to drive earlier diagnosis and better treatment and care to improve the chances of lung cancer survival.

The LCC is a group borne from our partnership with the World Economic Forum, whose membership spans healthcare delivery, research, diagnostics, biopharma, patient advocacy, and non-governmental organisations.

For an overview of the report, please click here. To read the full report, click here.

Kelly McCain, Head, Healthcare Initiatives, World Economic Forum, said: “Raising the standards of care in lung cancer is imperative if we are to reduce the global burden of cancer. The Lung Cancer Collaboration represents an important global and co-ordinated approach to provide more equitable access to lung cancer care. For too long, lung cancer has not been given the policy attention it deserves due to its links with tobacco use, but it is not purely a smokers and former smokers disease, with air pollution, occupational exposure and genetic predisposition, all significant risk factors.”i, ii

Mohit Manrao, Global Franchise Head, Lung Cancer, AstraZeneca, said: “This report is an important step forward in the ongoing efforts of the Lung Ambition Alliance to eliminate lung cancer as a cause of death. The pandemic has shown us, in healthcare especially, the power of pooling expertise and public/private resources to affect real change. By working together through multi-stakeholder partnerships, we can deliver sustainable improvements to health systems around the world and, ultimately, reduce the global burden of lung cancer.”

The LCC was established in response to the rising global burden of lung cancer, uniting a diverse array of organisations from both the commercial and non-profit sectors in a shared mission to advance lung cancer survival. The report outlines recommendations across three core areas. Underlying all is the need to ensure equitable access to all forms of lung cancer diagnosis, care and treatment:

1. Early detection and screening

We must demonstrate a compelling case for the adoption of targeted lung cancer screening and early detection. A shift in diagnosis from late- to early-stage forms of lung cancer is one of the most effective ways to decrease cancer mortality, and health services worldwide need support and funding to prioritise early diagnosis and treatment of lung cancer.iii

It is essential that countries do more to reach high-risk populations by identifying standards for uniform screening protocols in lung nodule management.iv,v Countries are also encouraged to utilise new technologies, such as liquid biopsies and artificial intelligence (AI) supported imaging, to help make initial screening easier and more accessible.vi,vii,viii,ix,x

2. Quality of treatment and care

Delays in diagnosis and access to treatment, as well as disparities in care, can adversely affect lung cancer survival outcomes.xi,xii To increase the number of people receiving appropriate treatment and care, at the right time, countries need to be equipped to be able to provide treatment and care that improves outcomes.

To minimise delays and differences, countries should aim to substantially reduce the time from first patient interaction, diagnosis, and treatment initiation through the adoption of an appropriately baseline-timed pathway.xiii,xiv,xv A multidisciplinary team (MDT) approach should also be taken to treatment and care, and investment in accessible lung cancer care technologies should be increased to help standardise patients’ access to, and experience of, high-quality care.xvi,xvii,xviii,xix

3. Finance and infrastructure

The current and future cost of lung cancer on healthcare systems, individuals and societies is significant.xx,xxi Countries need to prioritise investment in lung cancer more broadly. Investment decisions should be assessed through a cost-benefit and social impact analysis to ensure that they are targeted at areas of greatest need and impact, coupled with metrics to drive measurement on the impact of the investment.xxii,xxiii,xxiv Countries must also look holistically at all the possible funding for lung cancer, exploring and realising the potential of alternative funding sources.

Lung cancer is detectable, treatable and can be survivable.xxv,xxvi The recommendations of this report, combined with preventative measures outlined in the WHO Framework Convention on Tobacco Control, can propel lung cancer diagnosis and treatment forward and improve survivorship for patients.

i “Lung cancer in Europe: The way forward”, Health Policy Partnership, February 2022, https://www.healthpolicypartnership.com/app/uploads/Lung-cancer-in-Europe-the-way-forward.pdf.
ii “Lung cancer risk factors”, American Cancer Society, October 2019, https://www.cancer.org/cancer/lung-cancer/causes-risks-prevention/risk-factors.html
iii Goldstraw, P, et al., “The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer”, Journal of Thoracic Oncology, 11, 2016, pp. 39–51.
iv Wood, DE, et al., “Lung Cancer Screening, version 1.2022.NCCN Clinical Practice Guidelines in Oncology”, NCCN, 2022, https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1441.
v Smeltzer, M, et al., “Lung cancer diagnosed by an incidental lung nodule programme or lung cancer screening”, Journal of Clinical Oncology, 37(15), May 2019, pp. 8546-8546.
vi Luo, H, et al., “Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA”, Trends in Molecular Medicine, 27(5), May 2021, pp. 482-500, https://www.cell.com/trends/molecular-medicine/fulltext/S1471-4914(21)00002-2?_returnURL=
vii Mathew, CJ, David, AM, Mathew, CMJ, “Artificial intelligence and its future potential in lung cancer screening", EXCLI Journal 2020; 19:1552-1562, https://doi.org/10.17179/excli2020-2095
viii Espinoza, JL , Dong, LT, “Artificial intelligence tools for refining lung cancer screening”, Journal of Clinical Medicine, 9(12), December 2020, p. 3860, https://doi.org/10.3390/jcm9123860.
ix Kwong, GA, et al., “Synthetic biomarkers: a twenty-first century path to early cancer detection”, Nature Reviews Cancer, 21(10), October 2021, pp. 655-668, https://doi.org/10.1038/s41568-021-00389-3.
x Raghavan, D, et al., “Effectiveness of mobile computerized tomographic (CT) lung scanning unit for early diagnosis of lung cancer in under-served populations”, Journal of Clinical Oncology, 37(15), 2019, https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.6567
xi Jacobsen, MM, et al., “Timeliness of access to lung cancer diagnosis and treatment: A scoping literature review”, Lung Cancer, August 2017, https://www.lungcancerjournal.info/article/S0169-5002(17)30472-5/fulltext.
xii National Cancer Institute. Multipronged approach eliminates racial disparities in early-stage lung cancer treatment. 2019. Accessed May 2022. https://www.cancer.gov/news-events/cancer-currents-blog/2019/lung-cancer-treatment-disparities-eliminated
xiii Jensen, H, et al., “Diagnostic intervals before and after implementation of cancer patient pathways – a GP survey and registry-based comparison of three cohorts of cancer patients”, BMC Cancer, 15(1), 2015, pp. 308-18, https://doi.org/10.1186/s12885-015-1317-7.
xiv “Danish Cancer Patient Pathways: three-legged strategy for faster referral and diagnosis of cancer”, All.Can, https://www.all-can.org/efficiency-hub/danish-cancer-patient-pathways-three-legged-strategy-for-faster-referral-and-diagnosis-of-cancer/.
xv “Delivering cancer waiting times: A good practice guide”, NHS, 2015, https://www.england.nhs.uk/wp-content/uploads/2015/03/delivering-cancer-wait-times.pdf.
xvi “All about multidisciplinary care”, Australian Government, Cancer Australia, https://www.canceraustralia.gov.au/clinicians-hub/multidisciplinary-care/all-about-multidisciplinary-care.
xvii “Optimal Resources for Cancer Care: 2020 Standards”, Commission on Cancer, American College of Surgeons, updated April 2022, https://www.facs.org/Quality-Programs/Cancer/CoC/standards/2020.
xviii Johnston, B, et al., “Outcomes of the Kaiser Permanente Tele-Home Health Research Project”, National Institute for Health Research, 9(1), January 2000, pp. 40-5, https://www.crd.york.ac.uk/crdweb/PrintPDF.php?AccessionNumber=22000000324&Copyright=NHS+Economic+Evaluation+Database+%28NHS+EED%29%3Cbr+%2F%3EProduced+by+the+Centre+for+Reviews+and+Dissemination+%3Cbr+%2F%3ECopyright+%26copy%3B+2019+University+of+York%3Cbr+%2F%3E&AccessionNumber=22000000324&Copyright=NHS+Economic+Evaluation+Database+%28NHS+EED%29%3Cbr+%2F%3EProduced+by+the+Centre+for+Reviews+and+Dissemination+%3Cbr+%2F%3ECopyright+%26copy%3B+2019+University+of+York%3Cbr+%2F.
xix “Lung cancer treatment during a pandemic: How have multidisciplinary teams changed?”, MSD, March 2021, https://www.lcnuk.org/sites/lcnuk.org/files/sites/default/files/GB-NON-04040%20-%20Lung%20cancer%20MDT_FINAL.pdf.
xx Luengo-Fernandez, R, et al., “Economic burden of cancer across the European Union: a population-based cost analysis”, Lancet Oncology, 14(12), 2013, pp. 1165-74, https://doi.org/10.1016/S1470-2045(13)70442-X.
xxi “GBD Results Tool”, Institute for Health Metrics and Evaluation, University of Washington, 2019, https://ghdx.healthdata.org/gbd-results-tool.
xxii “Economic value as a guide for investing in health and care”, MedTech Europe, 2016, https://www.medtecheurope.org/wp-content/uploads/2016/08/ECONOMIC-VALUE-AS-A-GUIDE-FOR-INVESTING-IN-HEALTH-AND-CARE-Policy-Framework_3.pdf.
xxiii Cylus, J, Permanand, G, Smith, PC, “Making the economic case for investing in health systems”, WHO: European Observatory on Health Systems and Policies, 2019. https://www.euro.who.int/__data/assets/pdf_file/0010/380728/pb-tallinn-01-eng.pdf
xxiv “Patient Reported Outcome Measures (PROMS)”, NHS Digital, n.d., https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/patient-reported-outcome-measures-proms.
xxv “Tests for Lung Cancer”, Cancer Research UK, n.d., ., https://www.cancerresearchuk.org/about-cancer/lung-cancer/getting-diagnosed/tests.
xxvi “Why is early diagnosis important?”, Cancer Research UK, January 2021, https://www.cancerresearchuk.org/about-cancer/cancer-symptoms/why-is-early-diagnosis-important?source=content_type%3Areact%7Cfirst_level_url%3Aarticle%7Csection%3Amain_content%7Cbutton%3Abody_link.

Date of Preparation: May 2022 | Document ID: Z4-44754